For the first time since 2019, our team attended one of the signature global events for the interventional cardiovascular community: EuroPCR. The course is an opportunity to engage with the physician community to demonstrate our technology, and we welcomed the return to an in-person event. Two years have passed since the last event, which provided a fresh perspective on how clinicians view robotic technologies.

Wayne Markowitz, Worldwide Executive Vice President and Head of Corindus and Carrie Vooght, Head of Clinical Affairs, both attended EuroPCR and shared their key takeaways: 

The evolutionary path of our CorPath^® GRX is approaching several major milestones in 2022 that mark the next steps in our mission to revolutionize interventional treatment and expand access to care. The demand for innovative and transformative technology has never been greater and we are poised to meet the market’s demand for innovation.

As we close 2021 and look ahead to the new year, these are some of the projects that will reshape our technology in 2022:

Healthcare providers around the world have set out on a mission to achieve one thing: predictability. In the aftermath of a pandemic that has been anything but predictable, every stakeholder in the healthcare continuum has a vested interest in making it easier to predict positive patient outcomes.